Treatment of HSV-1 (herpes simplex virus type 1) skin florescence of skin types I-III with the diode laser compared to standard treatment with the antiviral drug aciclovir

Treatment of HSV-1 (herpes simplex virus type 1) skin florescence of skin types I-III with the diode laser compared to standard treatment with the antiviral drug aciclovir - HSV-1

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028059

Enrollment

Registered

2022-04-13

Start date

2023-01-02

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B00.1

Interventions

Group 1: Lip region: Ointment therapy with the active substance aciclovir > ointment is given every 2-3 hours according to the manufacturer’s recommendation by the study subject. Application is done

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients aged 18 years and older with a regularly recurring HSV-1 infection regardless of gender can participate in the study. The region of infection should be located in the red of the lips or in the near lip margin area.

Exclusion criteria

Exclusion criteria: 1) Skin type above III 2) Light intolerance 3) Vascular disorders 4) Diabetic mellitus 5) Continuous medication (immunosuppressants, antibiotics, antihistamines, analgesics) 6) Antivirals in the last ¼ year. 7) No permanent makeup around/or in the red of the lips 8) Smokers 9) Pregnant patients 10) Patients under 18 years of age 11) Kidney disease The aim of the exclusion criteria is to reduce external/internal interfering factors. Furthermore, light absorption and light propagation are optimized.

Design outcomes

Primary

Measure	Time frame
The effect of diode laser treatment compared to standard treatment with the antiviral aciclovir in skin florescence is investigated. Investigations of skin florescence reduction and pain sensation will take place after 24 hours. The change in inflammation is determined with the Mexamter. The Mexameter is a non-invasive, painless measurement. The pain sensation is documented with the visual analog scale (VAS pain scale).	—

Measure

Time frame

The effect of diode laser treatment compared to standard treatment with the antiviral aciclovir in skin florescence is investigated. Investigations of skin florescence reduction and pain sensation will take place after 24 hours. The change in inflammation is determined with the Mexamter. The Mexameter is a non-invasive, painless measurement. The pain sensation is documented with the visual analog scale (VAS pain scale).

—

Secondary

Measure	Time frame
Objective: Diode laser treatment should be used more for the treatment of herpes type 1 if the following is true: The erythema (inflammation) score after diode laser treatment is reduced more than in the control group treated with antiviral. The success of laser treatment for HSV-1 infection is independent of skin type I-III. The clinical parameter "pain" decreases more under laser treatment than under ointment treatment. The skin change can be used for follow-up.	—

Measure

Time frame

Objective: Diode laser treatment should be used more for the treatment of herpes type 1 if the following is true: The erythema (inflammation) score after diode laser treatment is reduced more than in the control group treated with antiviral. The success of laser treatment for HSV-1 infection is independent of skin type I-III. The clinical parameter "pain" decreases more under laser treatment than under ointment treatment. The skin change can be used for follow-up.

—

Countries

Germany

Contacts

Public ContactJaconòt Deumer

Erstes zahnärztliches Lasercentrum Berlin GmbH

jaconot.deumer@gmail.com030 31806126

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026